287 related articles for article (PubMed ID: 31324407)
21. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
Gebauer K; Reinecke H
Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
[TBL] [Abstract][Full Text] [Related]
22. A Clinical Guide to Combination Lipid-Lowering Therapy.
Russell C; Sheth S; Jacoby D
Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
[TBL] [Abstract][Full Text] [Related]
23. Poststatin Lipid Therapeutics: A Review.
Jia X; Lorenz P; Ballantyne CM
Methodist Debakey Cardiovasc J; 2019; 15(1):32-38. PubMed ID: 31049147
[TBL] [Abstract][Full Text] [Related]
24. Determinants of Achieved LDL Cholesterol and "Non-HDL" Cholesterol in the Management of Dyslipidemias.
Packard CJ
Curr Cardiol Rep; 2018 Jun; 20(8):60. PubMed ID: 29904807
[TBL] [Abstract][Full Text] [Related]
25. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS
Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965
[TBL] [Abstract][Full Text] [Related]
26. Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: Two-year experience of a regional lipid clinic.
Zafrir B; Jubran A
Cardiovasc Ther; 2018 Oct; 36(5):e12439. PubMed ID: 29863817
[TBL] [Abstract][Full Text] [Related]
27. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
28. An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome.
Drexel H; Coats AJS; Spoletini I; Bilato C; Mollace V; Perrone Filardi P; Rosano GMC
Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):115-121. PubMed ID: 31873726
[TBL] [Abstract][Full Text] [Related]
29. Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events.
Lee S; Cannon CP
Curr Cardiol Rep; 2018 May; 20(7):55. PubMed ID: 29802475
[TBL] [Abstract][Full Text] [Related]
30. [A decade of progress in the management of dyslipidemia].
Wallemacq C; Paquot N
Rev Med Liege; 2020 May; 75(5-6):386-391. PubMed ID: 32496685
[TBL] [Abstract][Full Text] [Related]
31. [Eligibility for the indication of PCSK9 inhibitors according to the recommendations of different scientific societies].
Siniawski D; Masson W; Rossi E; Damonte J; Halsband A; Pizarro R
Medicina (B Aires); 2019; 79(2):104-110. PubMed ID: 31048275
[TBL] [Abstract][Full Text] [Related]
32. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
33. Implications for REDUCE IT in clinical practice.
Bittner V
Prog Cardiovasc Dis; 2019; 62(5):395-400. PubMed ID: 31715195
[TBL] [Abstract][Full Text] [Related]
34. Meta-analysis of the Relation of Body Mass Index to Cardiovascular Outcomes in Patients Receiving Intensive Low-Density Lipoprotein Cholesterol Lowering Therapy.
Khan SU; Khan MU; Riaz H; Raggi P; Valavoor S; Khan MZ; Kołodziejczak M; Khan MS; Krupica T; Alkhouli M; Navarese EP
Am J Cardiol; 2020 Mar; 125(5):727-734. PubMed ID: 31898964
[TBL] [Abstract][Full Text] [Related]
35. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
Wójcik C
Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791
[TBL] [Abstract][Full Text] [Related]
36. LDL-cholesterol: The lower the better.
Pedro-Botet J; Pintó X
Clin Investig Arterioscler; 2019 Dec; 31 Suppl 2():16-27. PubMed ID: 31813618
[TBL] [Abstract][Full Text] [Related]
37. Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.
Karalis DG; Mallya UG; Ghannam AF; Elassal J; Gupta R; Boklage SH
Am J Cardiol; 2018 May; 121(10):1155-1161. PubMed ID: 29548678
[TBL] [Abstract][Full Text] [Related]
38. Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors.
Scherer DJ; Nelson AJ; Psaltis PJ; Nicholls SJ
Intern Med J; 2017 Aug; 47(8):856-865. PubMed ID: 28401639
[TBL] [Abstract][Full Text] [Related]
39. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP
Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086
[TBL] [Abstract][Full Text] [Related]
40. [Up to date lipid lowering treatment].
Paragh G; Karádi I
Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
